In vitro effects of recombinant human growth hormone on growth of human gastric cancer cell line BGC823 cells

Jia-Yong Chen, Dao-Ming Liang, Ping Gan, Yi Zhang, Jie Lin

AIM: To study the effects of recombinant human growth hormone (rhGH) on growth of human gastric cancer cell line in vitro.

METHODS: Experiment was divided into control group, rhGH group, oxaliplatin (L-OHP) group and rhGH+L-OHP group. Cell inhibitory rate, cell cycle, cell proliferation index (PI) and DNA inhibitory rate of human gastric cancer line BGC823, at different concentrations of rhGH treatment were studied by cell culture, MTT assay and flow cytometry.

RESULTS: The distinctly accelerated effects of rhGH on multiplication of BGC823 cell line were not found in vitro. There was no statistical significance between rhGH group and control group, or between rhGH+L-OHP group and L-OHP group (P>0.05). The cell growth curve did not rise. Cell inhibitory rate and cells arrested in G2-M phase were obviously increased. Meanwhile, cells in S phase and PI were distinctly decreased and DNA inhibitory rate was obviously increased in rhGH+L-OHP group in comparison with control group and rhGH group, respectively (P<0.01). Cell inhibitory rate showed an increasing trend and PI showed a decreasing trend in rhGH+L-OHP group compared with L-OHP group.

CONCLUSION: In vitro rhGH does not accelerate the multiplication of human gastric cancer cells. It may increase the therapeutic efficacy when it is used in combination with anticancer drugs.

Chen JY, Liang DM, Gan P, Zhang Y, Lin J. In vitro effects of recombinant human growth hormone on growth of human gastric cancer cell line BGC823 cells. World J Gastroenterol 2004; 10(8): 1132-1136

http://www.wjgnet.com/1007-9327/10/1132.asp

INTRODUCTION

Human growth hormone (rhGH) promotes protein synthesis and lipid mobilization and accelerates nitrogen balance. It is extensively applied in clinic for the adjustment of metabolic state in patients with severe trauma, burn or major operations. It was reported that recombinant human growth hormone (rhGH) was also applied in postoperative patients with tumor, but it is controversial whether rhGH accelerates the growth of tumor cells. In the present study we investigated the effects of rhGH on human gastric cancer cell line BGC823 in vitro, in order to clarify whether rhGH could be applied in postoperative patients with gastric cancer.

MATERIALS AND METHODS

Materials

Human gastric cancer cell line BGC823 was supplied by the cell bank of Shanghai Cell Biology Institute of Chinese Academy of Sciences. rhGH (Saizen) was supplied by Serono (Switzerland), one IU equals to 0.33 mg and the final concentration of rhGH was 50 ng/mL, 100 ng/mL, 200 ng/mL and 400 ng/mL respectively. Oxaliplatin (L-OHP) was selected as an anti-cancer drug supplied by Henriui Medical Company, Jiangsu, China, and its final concentration was 4 µg/mL. The main instruments were ELISA (EL340) and flow cytometry (EPICXU).

Methods

Experiment was divided into 4 groups: control group (I), anti-cancer drug group (II), rhGH group (III) and rhGH+anti-cancer drug group (IV) (Table 1).

| Groups | Names and concentrations of drugs |
|--------|----------------------------------|
| I      | RPMI1640                         |
| II     | L-OHP 4 µg/mL                    |
| IIIa   | rhGH 50 ng/mL                    |
| IIIb   | rhGH 100 ng/mL                   |
| IIIc   | rhGH 200 ng/mL                   |
| IIId   | rhGH 400 ng/mL                   |
| IVa    | rhGH 50 ng/mL + L-OHP 4 µg/mL    |
| IVb    | rhGH 100 ng/mL + L-OHP 4 µg/mL   |
| IVc    | rhGH 200 ng/mL + L-OHP 4 µg/mL   |
| IVd    | rhGH 400 ng/mL + L-OHP 4 µg/mL   |

BGC823 cells were placed in the medium containing 100 mL calf serum and RPMI1640, incubated at 37 °C in an atmosphere containing 50 mL CO2 and 950 mL air. At logarithmic growth, the cells were digested by trypsin. Then the activity of the cells was examined (Via=99%) and the cells were counted in a hemocytometer using trypsin blue exclusion. The density of single cell suspension was adjusted to 1x10^5/mL for use.

Single-cell suspension was added into a 96-well plate and 90 µL suspension was added to each well and there were 4 duplicate wells in each group. When the cells completely adhered to the wall of the well 4 h later, 10 µL test drugs was added into the wells (In rhGH+L-OHP group, the ratio of the volume of both drugs was 1:1). The cells were cultured for 1, 2, 3 and 4 d, respectively, at 37 °C in an atmosphere containing 50 mL CO2 and 950 mL air. In addition, the cells were cultured as above for 48 h to examine cell inhibitory rates. A 10 µL
MTT (5 mg/mL) was added to each well 4 h prior to the ending of experiment. When the experiment ended, 100 µL triplicate liquid [100 g/L SDS-50 mL/L iso-butyl alcohol-0.012 mL/L HCl] was added into each well. Absorbent value of each well was examined at the wavelengths 570 nm and 630 nm by ELISA 12 h later.

A 10 mL cell suspension was placed and incubated in each well of 6-well plates and there were 3 duplicate wells in each group. When the cells completely adhered to the wall of wells 4 h later, the test drugs were added into each well as shown in Table 2.

Table 2 Scheme of drugs in each group

| Group | I   | II  | IIIa | IIIb | IIIc | IVa  | IVb  | IVc  | IVd  |
|-------|-----|-----|------|------|------|------|------|------|------|
| L-OHP (µL) | /   | 50  | /    | /    | /    | 50.0 | 50   | 50   | 50   |
| rhGH (µL) | /   | 12.5| 25   | 50   | 100  | 12.5 | 25   | 50   | 100  |
| RPM1640 (µL) | 150 | 100 | 137.5| 125  | 100  | 50  | 75   | 50   | /    |

The cells were gathered after cultured for 48 h and washed with PBS. After fixed with 700 mL/L alcohol, the cells were kept at 4 °C overnight, then stained with fluorescein. Finally the cell cycle was examined at the wavelength 488 nm. Barlogie cell cycle assay was used[1].

Statistical analysis
Data were expressed as mean±SD and analyzed by variance analysis and q test. Statistical significance was considered at $P<0.05$.

RESULTS

MTT colorimetric analysis
The inhibitory rate on gastric cancer cells was significantly higher in L-OHP group and rhGH+L-OHP group, compared with control group and rhGH group ($P<0.01$). The inhibitory rate was also higher in rhGH+L-OHP group than in L-OHP group, though the difference had no statistical significance ($P>0.05$). Between control group and rhGH group, the inhibitory rate did not change regularly with increase of the drug’s dose (Table 3).

Table 3 Effects of rhGH and L-OHP on BGC823 cells (n=4, mean±SD)

| Groups | OD values | Survival rate (%) | Inhibitory rate (%) |
|--------|-----------|-------------------|---------------------|
| I      | 0.863±0.172 | 100.00            | 0                   |
| II     | 0.425±0.086  | 49.25             | 50.75               |
| IIIa   | 0.947±0.142  | 109.73            | -9.73               |
| IIIb   | 0.894±0.220  | 103.59            | -3.59               |
| IIIc   | 0.848±0.346  | 96.26             | 1.74                |
| IVa    | 0.644±0.196  | 97.79             | 2.21                |
| IVb    | 0.338±0.240  | 39.17             | 60.83               |
| IVc    | 0.318±0.038  | 36.85             | 63.15               |
| IVd    | 0.318±0.018  | 36.85             | 63.15               |
| IVe    | 0.306±0.200  | 35.46             | 64.54               |

*b* $P<0.01$ vs control group or rhGH group.

Cell growth curve
Cell growth curve shows no obvious change between rhGH group and control group or between rhGH+L-OHP group and L-OHP group (Figures 1-2). But it dropped sharply when rhGH+L-OHP and L-OHP groups were compared with the control group.
Figure 3 Percentages of cells in G0-G1 phase (%).

Figure 4 Percentage of cells in S phase (%).

Figure 5 Percentage of cell in G2-M phase (%).

Figure 6 Cell PI (%).

**Proliferation Index (PI)**

PI was obviously reduced in L-OHP group compared with rhGH group or control group (P<0.01), but there was no statistical significance between rhGH+L-OHP group and L-OHP group, or between rhGH group and control group (P>0.05). PI showed a decreasing trend in rhGH+L-OHP group compared with L-OHP group (Table 5, Figure 6).

**Table 5** Proliferation index in each group (n=3, mean±SD)

| Group | PI            |
|-------|---------------|
| I     | 52.25±0.78    |
| II    | 16.15±1.77    |
| IIIa  | 46.97±6.31    |
| IIIb  | 47.67±6.55    |
| IIIc  | 47.67±6.94    |
| IIId  | 48.73±5.94    |
| IVa   | 14.93±2.62    |
| IVb   | 13.53±2.07    |
| IVc   | 14.47±0.47    |
| IVd   | 13.87±2.87    |

*P<0.01 vs control group or rhGH group.

**DNA inhibitory rate**

DNA inhibitory rate was obviously increased in rhGH+L-OHP group (group IV) compared with rhGH group (group III) (P<0.01) (Table 6, Figure 7).

**Table 6** DNA inhibitory rate in rhGH group and rhGH+L-OHP group (n=3, mean±SD)

| Group | DNA inhibitory rate (%) |
|-------|-------------------------|
| IIIa  | 111.1±9.4               |
| IVa   | 178.1±6.8               |
| IIIb  | 109.5±9.8               |
| IVb   | 181.0±6.0               |
| IIIc  | 109.5±0.5               |
| IVc   | 178.2±1.9               |
| IIId  | 107.2±12.4              |
| IVd   | 180.3±7.6               |

**DISCUSSION**

L-OHP is a new platinum compound that has the similar effects to cisplatin and carboplatin. The main mechanism of L-OHP is that it makes DNA broken by inserting platinum atom between two neighboring guanines or between guanine and adenosine in DNA, thus, DNA can not replicate or transcript. It is not a cell circle-specific anticancer drug. We determined its concentration in vitro, by referring to the maximal concentration in human plasma when the drug was used in pharmacological doses, and according to Limburg and Heckman formula. On the basis of this concentration, we devised the concentration gradient, and found the IC50 that L-OHP affected BGC823 cells was 4 µg/mL by sifting experiment of anti-cancer drugs in vitro.

The majority of data reported that the concentration of rhGH in vitro was 50 ng/mL or 100 ng/mL. Qi et al devised the super-high concentration of 200 ng/mL according to its clinical
application. In addition, Estrov et al. suggested that rhGH could accelerate human leukemia cell proliferation at high concentrations (250–300 ng/mL), so we proposed this concentration. The duration of the drug treatment was 48 h according to the double proliferation time of BGC823 cells.

rhGH is secreted by pituitary gland, it can reverse many nutritional and metabolic abnormalities associated with severe cachectic states. It has been shown that rhGH can promote protein synthesis, improve nitrogen balance, accelerate wound healing, maintain host immune function and alleviate postoperation fatigue syndrome (POF) [2,12]. GH has become available for clinical use. It was reported that rhGH enhanced positive nitrogen balance in metabolic recuperation of postoperative patients with malignant tumor [13,14]. But it is still controversial whether rhGH should be used in postoperative tumor patients since hGH promotes the proliferation of normal cells, as well as tumor cells. Estrov et al. reported rhGH could increase the risk of human leukemia and solid tumor at a high concentration. Ogilvy-Stuart et al. thought rhGH was associated with the increasing risk for tumor, especially for colon cancer, when it was used at a high concentration in patients with tumor. Akaza et al. found rhGH promoted carcinogenesis of chemically induced rat urinary bladder cancer. Ng et al. reported rhGH could increase the proportion of aneuploid cells in tumor-bearing rats. Some other studies showed that rhGH enhanced tumor growth [18,20]. However, Harrison et al. reported that rhGH did not prompt human pancreatic carcinoma growth. Tacke et al. thought that postoperative treatment with rhGH in a short term led to a faster recovery of the immune function, increased the activity of NK cells, helped clear away potential cancer cells, and inhibited the recurrence of tumor. Fiebig et al. also reported in vitro and in vivo rhGH did not promote tumor cells to proliferate. Bartlett et al. suggested rhGH inhibited tumor growth in protein-starved animals. Still, some other studies reported that rhGH did not increase tumor growth [26,27].

In the present study, the effects of rhGH on gastric tumor cells in vitro were investigated. The results showed that there was no apparent tumor growth stimulation. There were no distinct differences in survival rate, inhibitory rate, the number of cells in G1, G2-M phase, S and G2-M phase, PI and cell growth curve between rhGH group and control group or between rhGH+L-OHP group and L-OHP group (P>0.05). The results coincided with other clinical reports [24] and showed that it did not increase gastric cancer cell growth in vitro after rhGH was administered. In addition, the cell percentage in proliferation phase (S and G2-M phase) was not obviously different between rhGH+L-OHP group and L-OHP group (P>0.05), demonstrating that rhGH did not stimulate tumor cell proliferation. The cell inhibitory rate was distinctly increased, the cell percentage of S and G2-M phase and PI was decreased (P<0.05) and the cell growth curve was apparently dropped between rhGH+L-OHP group and control group, and between rhGH+L-OHP group and rhGH group. The cell inhibitory rate showed an increasing trend and PI showed a decreasing trend in rhGH+L-OHP group compared with L-OHP group (P>0.05). These results indicated rhGH could enhance L-OHP effect on tumor cells. It provides support for the practice that tumor patients should be treated by metabolic recuperation after operation or that in advanced cancer and inoperative patients the cachexia was improved, or in chemotherapeutic patients the adverse effect was alleviated by use of rhGH.

The mechanism of rhGH underlying tumor cell proliferation is unknown. Some reports showed rhGH could indirectly stimulate tumor cell proliferation by combining with IGF-1 receptors on the surface of tumor cells [28–32] but others showed that rhGH did not promote liver cancer cell proliferation because of reduced IGF-1 receptor expression [33,34]. Wembo et al. found that the activation of prolactin receptors but not mammary tumor induced by growth hormone receptors in transgenic mice. The exact mechanism of rhGH underlying gastrointestinal tumor cell proliferation is still unknown.

In conclusion rhGH does not promote gastric cancer cell proliferation and fission, on the contrary, it can enhance anti-cancer effects of drugs on gastric cancer cells in vitro.

REFERENCES

1. Barlogie B, Drewinko B, Schumann J. Freireich EJ. Pulse cytometric analysis of cell cycle perturbation with bleomycin in vitro. Cancer Res 1976; 36: 1182-1187
2. Yoshimura Y, Iwashita M, Karube M, Oda T, Akiba M, Shiokawa S, Ando M, Yoshinaga A, Nakamura Y. Growth hormone stimulates follicular development by stimulating ovarian production of insulin-like growth factor-1. Endocrinology 1994; 135: 887-894
3. Qi XP, Li JS, Chen C. Effect of human growth hormone on cell cycle kinetics in Lovo and LS-174-T cells. Nanjing Da Xue Xue Bao 2000; 36: 598-602
4. Qi XP, Li JS, Chen C. Effect of human growth hormone on cell cycle kinetics in colonic cancer cells. Changrui Yu Changhai Yingyang 2001; 8: 8-10
5. Estrov Z, Meir R, Barak Y, Zalozov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 1991; 9: 394-399
6. Raff T, Germann G. Growth hormone in surgery—an assessment of current knowledge. Chirurg 1997; 69: 995-1003
7. Ma EL. Changes of protein turnover in peripheric patients and effect of recombinant human growth hormone. Zhonghua Wai Ke Za Zhi 1992; 30: 631-634
8. Tacke J, Bolder U, Kohlen D. Improved cumulated nitrogen balance after administration of recombinant human growth hormone in patients undergoing gastrointestinal surgery. Infusionsther TRANSfusionsmed 1994; 21: 24-29
9. Gu Y, Wu ZH. The anabolic effects of recombinant human growth hormone and glutamine on parenterally fed, short bowel rats. World J Gastroenterol 2002; 8: 752-757
10. Chen HD, Xie JL, Lai W. The effect of combined treatment of recombinant human growth hormone and insulin-like growth factor-1 on wound healing and protein catabolism in burned rats. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1999; 13: 386-389
11. Agis-Torres A, Lopez-Oliva ME, Unzaga MT, Munoz-Martinez E. Body growth and substrate partitioning for fat and protein gain in weaned BALB/c mice treated with growth hormone. Comp Biochem Physiol A Mol Integr Physiol 2002; 132: 247-256
12. Mao Z, Chen R, Zhao L. Effect of recombinant human growth hormone on postoperative fatigue syndrome in patients after cardiac operations. Zhonghua Yi Xue Za Zhi 2002; 82: 762-765
13. Chen JY, Zhang J, Tan J, Gan P, Sun M, Chen XZ. Evaluation of human growth hormone on gastric and gastric cancer patients after surgery. Zhongguo Puai Ji Hu Yu Lin Chuang Zhi 1999; 6: 365-367
14. Guerrero JA, Capitan JM, Rosell J, Ruiz ME, Garcia E, Garcia-Carrizosa M, Maldonado MJ, Vara Thorbeck R. Effect of growth hormone and vitamin-E supplementation in patients undergoing major digestive surgery. Rev Esp Enferm Dig 1992; 81: 371-382
15. Ogilvy-Stuart AL, Ryder WD, Gattamaneni HR, Clayton PE, Shalet SM. Growth hormone and tumor recurrence. BMJ 1992; 304: 1001-1005
16. Akaza H, Matsuoka K, Matsuohama H, Koiso K, Aso Y. Stimulatory effects of growth hormone on rat bladder carcinogenesis. Cancer 1993; 68: 2418-2421
17. Ng EH, Rock CS, Lazarus D, Staiano-Coico L, Fischer E, Maldower LL, Lowy SF. Effect of exogenous growth hormone on host preservation and tumor cell-cycle distribution in a rat sarcoma model. J Surg Res 1991; 51: 99-105
18. Shalet SM, Brennan BM, Reddington RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 (Suppl 4): 29-32
19. Espat DJ, Chamberlain RS, Sklar C, Blumgart LH. Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner’s syndrome. Dig Surg 2000; 17: 640-643
20. Watanabe S, Kobayashi Y. Exogenous hormones and human cancer. Jpn J Clin Oncol 1993; 23: 1-13
21 Harrison LE, Blumberg D, Berman R, Ng B, Hochwald S, Brennan MF, Burt M. Effect of human growth hormone on human pancreatic carcinoma growth, protein and cell cycle kinetic. J Surg Res 1996; 61: 317-322

22 Tacke J, Bolder U, Herrmann A, Berger G, Jauch KW. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone. JPFEN 2000; 24: 140-144

23 Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone. Anticancer Drugs 2000; 11: 659-664

24 Fiebig HH, Dengler WA, Drees M, Ruhanu T. Human growth hormone is able to reduce tumor induced cachexia in a human tumor xenograft model without tumor stimulation. In: Sagesse G, Stanhope R, eds. Recent advances on growth and growth hormone therapy. London Freund 1995; 2: 239-251

25 Bartlett DL T, Stein P, Torosian MH, Philadelphia PA, Camden NJ. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 1995; 117: 260-267

26 Beentjes JA, van Gorkom BA, Sluiter WJ, de Vries EG, Kleibeuker JH, Dullaart RP. One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults. Clin Endocrinol 2000; 52: 457-462

27 Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704-1710

28 Rapaport R, Silis IN, Green L, Barrett P, Labus J, Skuza KA, Chartoff A, Goode L, Stene M, Petersen BH. Detection of human growth hormone receptor on IM cells and peripheral blood mononuclear cell subset by flow cytometry: Correlation with growth hormone-binding protein levels. J Clin Endocrinol Metab 1995; 81: 2612-2619

29 Lincoln DT, Kaiser HE, Raju GP, Waters MJ. Growth hormone and colorectal carcinoma: localization of receptor. In Vivo 2000; 14: 41-49

30 Nagano M, Chastre E, Choquet A, Bara J, Gespach C, Kelly PA. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995; 268 (3 Pt 1): G431-G442

31 Chopin L, Veeveris-Lowe T, Philippa A, Herington A. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm IGF Res 2002; 12: 126

32 Amit T, Hacham H, Daily O, Hertz P, Barkey RJ, Hochberg Z. The Hep G2 cell line in the study of growth hormone receptor/binding protein. Mol Cell Endocrinol 1994; 101: 29-36

33 Blanck A, Asefaw-Reddy Y, Eriksson LC, Gustafsson JA, Ekvam S, Hallstrom IP. Growth hormone administration after treatment in the resistant hepatocyte model does not affect progression of rat liver carcinogenesis. Cancer Lett 1994; 79: 193-198

34 Levinovitz A, Husman B, Eriksson LC, Norstedt G, Andersson G. Decreases expression of growth hormone receptor and growth hormone binding protein in rat liver nodules. Mol Cell Endocrinol 1999; 14: 157-164

35 Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OGP, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumor in transgenic mice. J Clin Invest 1997; 100: 2744-2751

Edited by Zhu LH and Wang XL  Proofread by Xu FM